Aridis Pharmaceuticals, Inc.
ARDS · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $5 | $20 | $8 | $21 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $1 | $0 | $0 | $0 |
| Inventory | $0 | -$0 | $0 | -$0 |
| Other Curr. Assets | $6 | $7 | $7 | $7 |
| Total Curr. Assets | $12 | $27 | $15 | $28 |
| Property Plant & Equip (Net) | $2 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $1 |
| Other NC Assets | $1 | $1 | $0 | $1 |
| Total NC Assets | $3 | $2 | $1 | $2 |
| Other Assets | $0 | -$2 | -$1 | -$2 |
| Total Assets | $15 | $27 | $15 | $28 |
| Liabilities | – | – | – | – |
| Payables | $2 | $5 | $2 | $2 |
| Short-Term Debt | $5 | $1 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $20 | $21 | $19 | $15 |
| Other Curr. Liab. | $10 | $7 | $1 | $3 |
| Total Curr. Liab. | $37 | $33 | $22 | $19 |
| LT Debt | $1 | $5 | $0 | $0 |
| Deferred Rev, NC | $1 | $1 | $1 | $5 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $2 | $7 | $1 | $5 |
| Other Liabilities | $0 | $1 | $0 | $0 |
| Cap. Leases | $2 | $0 | $0 | $0 |
| Total Liabilities | $39 | $41 | $24 | $24 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$196 | -$165 | -$123 | -$101 |
| AOCI | $5 | $0 | $0 | $0 |
| Other Equity | $166 | $152 | $114 | $104 |
| Total Equity | -$24 | -$13 | -$9 | $4 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $15 | $27 | $15 | $28 |
| Net Debt | $1 | -$14 | -$8 | -$21 |